Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation
Open Access
- 16 June 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 9 (12) , e014177
Abstract
Background: Dose adjustment of non‐vitamin K antagonist oral anticoagulants ( NOAC s) is indicated in some patients with atrial fibrillation ( AF ), based on selected patient factors or concomitant medications. We assessed the frequency of label adherence of NOAC dosing among AF patients and the associations between off‐label NOAC dosing and clinical outcomes. Methods and Results: We evaluated 53 649 AF patients treated with an NOAC using Korean National Health Insurance Service database during the period from 2013 to 2016. NOAC doses were classified as either underdosed or overdosed, consistent with Korea Food and Drug Administration labeling. Cox proportional hazards regression was performed to investigate the effectiveness and safety outcomes including stroke or systemic embolism, major bleeding, and all‐cause mortality. Overall, 16 757 NOAC ‐treated patients (31.2%) were underdosed, 4492 were overdosed (8.4%), and 32 400 (60.4%) were dosed appropriately according to drug labeling. Compared with patients with label adherence, those who were underdosed or overdosed were older (aged 71±8 and 75±7 years versus 70±9 years, respectively; P 2 DS 2 ‐ VAS c scores (4.6±1.7 and 5.3±1.7 versus 4.5±1.8, respectively; P P P P <0.001) compared with label‐adherent use. Conclusions: In real‐world practice, a significant proportion (almost 2 in 5) of AF patients received NOAC doses inconsistent with drug labeling. NOAC overdosing is associated with worse clinical outcomes in Asian AF patients.Keywords
This publication has 22 references indexed in Scilit:
- Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial FibrillationJACC, 2016
- New oral anticoagulants: appropriateness of prescribing in real‐world settingInternal Medicine Journal, 2016
- Data Analytic Process of a Nationwide Population-Based Study Using National Health Information Database Established by National Health Insurance ServiceDiabetes & Metabolism Journal, 2016
- Rate-Control Treatment and Mortality in Atrial FibrillationCirculation, 2015
- Background and Data Configuration Process of a Nationwide Population-Based Study Using the Korean National Health Insurance SystemDiabetes & Metabolism Journal, 2014
- Edoxaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2013
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery DiseaseNew England Journal of Medicine, 2008